Patents by Inventor Howard Levin

Howard Levin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220257315
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Application
    Filed: October 26, 2021
    Publication date: August 18, 2022
    Inventors: Howard LEVIN, Mark GELFAND, Zoar Jacob ENGELMAN, Dorin PANESCU, Mark S. LEUNG
  • Patent number: 11413090
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Grant
    Filed: January 19, 2021
    Date of Patent: August 16, 2022
    Assignee: Axon Therapies, Inc.
    Inventors: Pajhand Iranitalab, Casey Andrew Miller, Thomas Ryan McGrath, Manuel Arzadon Javier, Jr., Anisha Bapna, Zoar Jacob Engelman, Howard Levin, Nicholas C. VanDillen, Anne Marie Ahonen
  • Publication number: 20220230525
    Abstract: A system, method, and apparatus are provided to facilitate social distancing. The system issues alarms based on the distance between a user and an object and one or more variable social distancing thresholds. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and various characteristics.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 21, 2022
    Inventor: Howard Levin
  • Patent number: 11376066
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Grant
    Filed: September 2, 2021
    Date of Patent: July 5, 2022
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Patent number: 11367335
    Abstract: A system and associated equipment are provided to facilitate social distancing. The system issues alarms when the distance between a user and an object is at or below a social distancing threshold. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and user characteristics.
    Type: Grant
    Filed: April 19, 2021
    Date of Patent: June 21, 2022
    Inventor: Howard Levin
  • Publication number: 20220152302
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: November 24, 2021
    Publication date: May 19, 2022
    Inventors: Andrew V. HALPERT, Mark TAUSCHER, Mark GELFAND, Howard LEVIN
  • Patent number: 11305114
    Abstract: A system for treating disordered breathing of a human being includes an implantable transvenous stimulation lead having at least one stimulation electrode and a sensor configured to detect activity level of the human being. The system includes an energy source, a pulse generator and circuitry, the circuitry operative to receive a signal indicative of the activity level of the human being from the sensor, wherein the circuitry is configured to cause the energy source and the pulse generator to deliver spaced apart stimulation signals to the at least one stimulation electrode while the activity level of the human being is sufficiently low to be indicative of sleep. Spaced apart stimulation pulses from the electrode are configured to extend a duration of a time of at least one breath being defined as the time from an onset of inhalation to the onset of inhalation of a successive breath.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: April 19, 2022
    Assignee: ZOLL RESPICARDIA, INC.
    Inventors: Mark Gelfand, Howard Levin, Andrew Halpert, Antonis Panteleon
  • Publication number: 20220039863
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: October 22, 2021
    Publication date: February 10, 2022
    Inventors: Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan MCGRATH, Manuel Arzadon JAVIER, JR.
  • Publication number: 20220008725
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Application
    Filed: June 29, 2021
    Publication date: January 13, 2022
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20220000545
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: February 9, 2021
    Publication date: January 6, 2022
    Inventors: Howard LEVIN, Mark GELFAND
  • Patent number: 11213621
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: January 4, 2022
    Assignee: Reprieve Cardiovascular, Inc.
    Inventors: Andrew V. Halpert, Mark Tauscher, Mark Gelfand, Howard Levin
  • Publication number: 20210393326
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Application
    Filed: September 2, 2021
    Publication date: December 23, 2021
    Inventors: Howard LEVIN, Mark GELFAND
  • Patent number: 11154354
    Abstract: Apparatuses and methods for treating a heart failure patient by ablating a nerve of the thoracic splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method comprising: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying stimulation energy after the ablation and observing hemodynamic effects and monitoring for presence of the lung in the ablation zone. An alternative method comprising: inserting a catheter into a vein adjacent the nerve, detecting that lung tissue is a safe distance from an ablation zone, and delivering ablation energy to the target nerve when lung tissue is a safe distance from the ablation zone.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: October 26, 2021
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand, Zoar Jacob Engelman, Dorin Panescu, Mark S. Leung
  • Publication number: 20210327249
    Abstract: A system and associated equipment are provided to facilitate social distancing. The system issues alarms when the distance between a user and an object is at or below a social distancing threshold. The system enables trade-offs between risk and a desire to have in-person interaction for different activities by using one or more variable social distancing thresholds that may be based on social distancing guidelines and user characteristics.
    Type: Application
    Filed: April 19, 2021
    Publication date: October 21, 2021
    Inventor: Howard Levin
  • Publication number: 20210298824
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: June 11, 2021
    Publication date: September 30, 2021
    Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
  • Patent number: 11083894
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing secretion of endogenous atrial hormones by pacing of the heart. Pacing is done during the ventricular refractory period resulting in premature atrial contraction that does not result in ventricular contraction. Pacing results in the atrial wall stress, peripheral vasodilation, ANP secretion. Concomitant reduction of the heart rate is monitored and controlled as needed with backup pacing.
    Type: Grant
    Filed: March 20, 2019
    Date of Patent: August 10, 2021
    Assignee: BackBeat Medical, LLC
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20210220043
    Abstract: Systems, devices, and methods for transvascular ablation of target tissue. The devices and methods may, in some examples, be used for splanchnic nerve ablation to increase splanchnic venous blood capacitance to treat at least one of heart failure and hypertension. For example, the devices disclosed herein may be advanced endovascularly to a target vessel in the region of a thoracic splanchnic nerve (TSN), such as a greater splanchnic nerve (GSN) or a TSN nerve root. Also disclosed are methods of treating heart failure, such as HFpEF, by endovascularly ablating a thoracic splanchnic nerve to increase venous capacitance and reduce pulmonary blood pressure.
    Type: Application
    Filed: January 19, 2021
    Publication date: July 22, 2021
    Inventors: Pajhand IRANITALAB, Casey Andrew MILLER, Thomas Ryan McGRATH, Manuel Arzadon JAVIER, JR., Anisha BAPNA, Zoar Jacob ENGELMAN, Howard LEVIN, Nicholas C. VanDILLEN, Anne Marie AHONEN
  • Patent number: 10912610
    Abstract: A method for treating a heart failure patient by ablating a nerve of the splanchnic sympathetic nervous system to increase venous capacitance and reduce pulmonary blood pressure. A method including: inserting a catheter into a vein adjacent the nerve, applying stimulation energy and observing hemodynamic effects, applying ablation energy and observing hemodynamic effects, applying simulation energy after the ablation and observing hemodynamic effects.
    Type: Grant
    Filed: July 12, 2019
    Date of Patent: February 9, 2021
    Assignee: Axon Therapies, Inc.
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20200254252
    Abstract: A method and apparatus for treatment of hypertension and heart failure by increasing vagal tone and secretion of endogenous atrial hormones by excitory pacing of the heart atria. Atrial pacing is done during the ventricular refractory period resulting in atrial contraction against closed AV valves, and atrial contraction rate that is higher than the ventricular contraction rate. Pacing results in the increased atrial wall stress. An implantable device is used to monitor ECG and pace the atria in a nonphysiologic manner.
    Type: Application
    Filed: February 19, 2020
    Publication date: August 13, 2020
    Inventors: Howard Levin, Mark Gelfand
  • Publication number: 20200254178
    Abstract: A fluid therapy method for an ADHF patient includes setting a urine output rate desired threshold, setting one or more desired negative net gain rates, and optionally setting a total fluid loss goal. The urine output of the patient is monitored and fluid is automatically administered to the patient at increasing rates to equal to or approximately match the patient's increasing urine output rates until the patient's urine output rate reaches the set urine output rate desired threshold. Thereafter, fluid is administered to the patient at rates to achieve the set desired negative net gain rate until the fluid loss goal is reached. Thereafter, until the end of therapy, fluid is administered to the patient at rates equal to or approximately equal to the monitored urine output rates.
    Type: Application
    Filed: April 30, 2020
    Publication date: August 13, 2020
    Inventors: Andrew V. HALPERT, Mark TAUSCHER, Mark GELFAND, Howard LEVIN